Journal article
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey
Abstract
BACKGROUND: Although most cardiovascular disease occurs in low-income and middle-income countries, little is known about the use of effective secondary prevention medications in these communities. We aimed to assess use of proven effective secondary preventive drugs (antiplatelet drugs, β blockers, angiotensin-converting-enzyme [ACE] inhibitors or angiotensin-receptor blockers [ARBs], and statins) in individuals with a history of coronary heart …
Authors
Yusuf S; Islam S; Chow CK; Rangarajan S; Dagenais G; Diaz R; Gupta R; Kelishadi R; Iqbal R; Avezum A
Journal
The Lancet, Vol. 378, No. 9798, pp. 1231–1243
Publisher
Elsevier
Publication Date
10 2011
DOI
10.1016/s0140-6736(11)61215-4
ISSN
0140-6736
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Adrenergic beta-AntagonistsAdultAgedAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsCardiovascular AgentsCardiovascular DiseasesCoronary DiseaseData CollectionDeveloped CountriesDeveloping CountriesDrug UtilizationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPlatelet Aggregation InhibitorsRural PopulationSecondary PreventionStrokeUrban Population